Navigation Links
Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
Date:10/18/2010

Aranesp to a target hemoglobin of 13 g/dL or placebo. Due to the increased risk of negative outcomes associated with low hemoglobin levels, patients in the control arm whose hemoglobin fell below 9 g/dL were given Aranesp as a rescue medication until their hemoglobin level reached 9 g/dL. Investigators were blinded to this intervention.

The key findings from TREAT include:

  • The study failed to meet either of its primary endpoints of:
  • improving mortality and CV morbidity or
  • extending time to death or ESRD

  • TREAT showed:
  • An almost 2-fold increased risk of stroke (HR = 1.92 [95 percent CI: 1.38-2.68], annualized incidence rate 2.1 percent vs. 1.1 percent) in the Aranesp arm
  • Among patients with history of malignancy, a higher number of deaths due to any cause and of death adjudicated as due to malignancy in the Aranesp arm
  • Aranesp therapy significantly reduced the need for transfusions
  • A statistically-significant but clinically modest improvement in patient-reported outcomes for patients in the Aranesp arm

  • Chronic Kidney Disease: Impact and PrevalenceCKD affects more than 26 million Americans and millions more worldwide. The disease is characterized by progressive kidney damage and impaired kidney function and is most often caused by type-2 diabetes or high blood pressure. When CKD progresses to kidney failure, chronic dialysis or a kidney transplant are required to sustain life. Anemia is a common complication of CKD that may begin in the early stages of the disease and becomes more common and severe as kidney function declines.

    About AranespAranesp was approved by the FDA in 2001 for the treatment of anemia associated with CRF for patients on dialysis and patients not on dialysis. The European Commission granted marketing authorization for the same indication in 2001 and subsequently updated it for CRF patients with symptomatic anemia in 2008.

    In 2002, the
    '/>"/>

    SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
    2. Medarex to Receive Milestone Payment from Amgen
    3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
    4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
    6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
    7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
    8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
    9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
    10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
    11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
    (Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
    (Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
    Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
    ... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
    ... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
    Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
    (Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... labels and stickers to keep little ones' safety top of mind at all times. ... a particular focus. According to the JPMA's Baby Safety Zone website, this year's theme ...
    (Date:9/1/2015)... ... 01, 2015 , ... Curly Hair Solutions™ is thrilled to ... anticipated partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution ... the Curly Hair Solutions™ team could not be more delighted to see their ...
    (Date:8/31/2015)... Orange, NJ (PRWEB) , ... September 01, 2015 ... ... the spine to eliminate chronic back pain – once required a long, arduous ... a shorter hospital stay, less pain, less blood loss and minimal muscle damage. ...
    (Date:8/31/2015)... ... 31, 2015 , ... Cosmetic Town Journal is an online ... have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients ... ready to help. , It is clear that the Cosmetic Town aesthetic surgery ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... Southern Vacation Rentals ... has teamed up with fellow South Walton property management company, 360 Blue, ... poverty in remote parts of the world. The two companies will collect any unopened ...
    Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3
    ... , New York, NY, August 24, 2011 Nearly three-quarters (72%) ... their jobs over the last two years said that they ... because of cost, according to a new Commonwealth Fund ... or medical debt, compared to about half (49%) who lost ...
    ... Aug. 24 (HealthDay News) -- Exclusive breast-feeding of infants ... against developing the itchy skin disorder known as eczema ... an infant receives only breast milk, with no additional ... Exclusive breast-feeding up to 6 months of age is ...
    ... well as others in Canada and the United Kingdom, ... motion pictures that depict smoking -- leading to thousands ... California, San Francisco (UCSF) researcher has found. According ... those subsidies, along with government inaction on stricter ratings ...
    ... , TUESDAY, Aug. 23 (HealthDay News) -- A ... to worsen over time and may lead to an increased ... with diastolic dysfunction, which often comes with advancing age, the ... way and is accompanied by elevated filling pressures. The ...
    ... (IBD), which affects more than 1 million patients in ... by environmental factors, such as bacteria, in people genetically ... the lining of the colon, is one such condition. ... prompted by different cytokines small signaling proteins secreted ...
    ... Drug Administration,s ruling that Avastin should no longer be ... Phase III clinical trial shows that Avastin significantly increased ... before surgery. At the annual meeting for ... association of clinical oncologists, Harry D. Bear, M.D., Ph.D., ...
    Cached Medicine News:Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 2Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 3Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 4Health News:Breast-Feeding Won't Prevent Kids' Eczema, Researchers Say 2Health News:Taxpayer film subsidies promote youth smoking 2Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Novel cytokine protects mice from colitis 2Health News:Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients 2